Small Intestinal Carcinoma

In conclusion, aberrant mucin signatures reflect distinct molecular pathways in (pre)malignant GIT lesions and highlight their potential utility as biomarkers and therapeutic targets. Schematic representation of the main findings regarding altered mucin signalling in several precancerous lesions (adenomatous (i.e., conventional pathway 1) and serrated polyps (i.e. pathway 2)) and small intestinal (SIA) and colorectal (CRC) adenocarcinomas and its clinicopathological significance (outcome, anatomical location (proximal/distal), molecular subtypes (MSI, (non)-mucinous).

It underscores the importance of careful clinicopathological correlation and multidisciplinary evaluation in atypical metastatic scenarios, while illustrating how surgery can provide symptom control and enable systemic therapy. Given its rarity, these observations should be interpreted with caution and regarded as descriptive rather than generalizable.

Additionally, NaDF supplementation quadratically decreased the concentration of jejunal tumor necrosis factor alpha. Collectively, these findings demonstrate that NaDF enhances broiler growth performance probably by lowering gut pH, promoting nutrient digestion, modulating microbiota, and reducing intestinal inflammation, supporting its potential as a promising alternative to antibiotic growth promoters in poultry production.

Antiresorptive therapy may reduce SREs. Whether adapting NET treatment algorithm for BM improves OS needs to be tested in clinical trials.

The patient received ulinastatin and antibiotic therapy for pancreatic head tumor-induced acute pancreatitis...Diagnostic physicians should note that ITPNs have distinct margins, enhanced posterior echoes, and no internal low echoes due to their pathological structures. In addition, it is also important for diagnostic physicians to note that ITPN patients less often develop icterus due to both the mass softness and the lack of mucin production.

P2, N=80, Suspended, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2029 | Trial primary completion date: Jan 2026 --> Jan 2029

P=N/A, N=360, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Feb 2026 --> Jun 2026

This case suggests that preoperative and intraoperative imaging may not detect rare metastatic patterns, and that immunohistochemical analysis may help estimate tumor origin. Careful differentiation between true synchronous colorectal cancer and gastric cancer with intestinal metastases may help guide treatment decisions.

This case demonstrates the aggressive natural history of gallbladder SNEC. Early tissue diagnosis and prompt platinum-etoposide chemotherapy initiation while performance status permits remain critical for meaningful survival benefit.

P=N/A, N=3712, Completed, Medtronic - MITG | Active, not recruiting --> Completed | N=8000 --> 3712

These primary cultures, maintained between passages 5 and 10 to preserve phenotypic integrity, offer a valuable ex vivo model for early-stage CRC research and the screening of preventive agents. By bridging genetic susceptibility and translational prevention, this platform provides a novel and reproducible tool for advancing cancer interception.

P1/2, N=67, Active, not recruiting, Immunitas Therapeutics | Recruiting --> Active, not recruiting | N=151 --> 67 | Trial completion date: Apr 2025 --> Jan 2026 | Trial primary completion date: Apr 2025 --> Jan 2026